This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
by Zacks Equity Research
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
REGNPositive Net Change SNYPositive Net Change NVSPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
by Zacks Equity Research
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
NVSPositive Net Change BAYRYPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued momentum across its Diagnostics & Spatial Biology segment.
BSXNegative Net Change DGXPositive Net Change RMDPositive Net Change TECHNegative Net Change
biotechnology earnings medical
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
by Zacks Equity Research
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
biotechnology biotechs earnings medical
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
by Zacks Equity Research
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
NVSPositive Net Change BMRNNegative Net Change BAYRYPositive Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
NVSPositive Net Change BAYRYPositive Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
ALNYPositive Net Change MRKPositive Net Change EXELNegative Net Change AMRNPositive Net Change
biotechnology biotechs earnings pharmaceuticals
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change FATEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
by Zacks Equity Research
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
AZNPositive Net Change NVSPositive Net Change BAYRYPositive Net Change
biotechnology earnings medical pharmaceuticals
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
REGNPositive Net Change BIIBPositive Net Change NVOPositive Net Change ZTSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
REGNPositive Net Change SNYPositive Net Change BIIBPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
by Ekta Bagri
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs earnings-preview pharmaceuticals
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change COLLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.
VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
by Zacks Equity Research
Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article.
EXELNegative Net Change FOLDPositive Net Change CRSPPositive Net Change VRNANo Net Change
biotechnology
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
by Zacks Equity Research
FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.
MRKPositive Net Change TEVAPositive Net Change GILDNegative Net Change FOLDPositive Net Change EDITPositive Net Change
biotechnology biotechs pharmaceuticals
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change DTILNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
EXELNegative Net Change FOLDPositive Net Change CRSPPositive Net Change VRNANo Net Change
biotechnology biotechs crispr medical pharmaceuticals
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
by Zacks Equity Research
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
VRTXPositive Net Change ANIPNegative Net Change FATEPositive Net Change EDITPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Should You Buy Marriott International (MAR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MARNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
by Zacks Equity Research
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
REGNPositive Net Change RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology earnings medical pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
NVSPositive Net Change INCYPositive Net Change EXELNegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
by Zacks Equity Research
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
NVOPositive Net Change FOLDPositive Net Change ANIPNegative Net Change FATEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Acadia (ACAD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Acadia (ACAD) stock based on the movements in the options market lately.
ACADPositive Net Change
biotechnology biotechs medical
Ardagh Metal Packaging S.A. (AMBP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AMBPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines